AGArindam Ghatak

Arindam Ghatak

*This is an algorithmically generated author record based on publicly available information.

Arindam Ghatak has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reducing the vicissitudes of heterologous prochiral substrate catalysis by alcohol dehydrogenases through machine learning algorithms

    by Arindam Ghatak, Anirudh P. Shanbhag, Santanu Datta

    Alcohol dehydrogenases (ADHs) encompass three distinctive superfamilies: medium-chain dehydrogenase (MDRs), short-chain dehydrogenase (SDRs), and iron-containing alcohol dehydrogenases. MDRs and SDRs have pivotal roles in converting pro-pharmaceutical ketones into chiral alcohols, serving as active pharmaceutical intermediate catalysts in industries. Nevertheless, the pursuit of aligning enzymes to a one enzyme-one substrate paradigm is intricate and resource-intensive. This study undertook the catalysis of 284 antibacterial ketone intermediates, yielding distinct patterns for both MDRs and SDRs. We endeavored to leverage machine learning to discriminate between compounds subjected to the influence of these superfamilies. To this end, we curated a dataset comprising 33 features, encompassing 4 descriptors for each compound. Subsequently, an ensemble of machine learning techniques, including Partial Least Squares (PLS) regression, k-Nearest Neighbors (kNN) regression, and Support Vector Machine (SVM) regression, was harnessed. Furthermore, the assimilation of Principal Component Analysis (PCA) augmented precision and accuracy, refining compound classification and intensifying differentiation and demarcation within diverse compound classes. As such, this classification strategy emerged as a potent approach for discerning substrates amenable to diverse alcohol dehydrogenases, thereby mitigating the reliance on high-throughput screening in identifying the optimal enzyme for specific substrate preferences.

  • Effectiveness of a novel, non-intrusive, continuous-use air decontamination technology to reduce microbial contamination in clinical settings: a multi-centric study

    by S. Nagaraj, S. Chandrasingh, S. Jose, B. Sofia, S. Sampath, B. Krishna, I. Menon, D. Kundu, S. Parekh, D. Madival, et al.


  • Open Access

    Novel non intrusive continuous use ZeBox technology to trap and kill airborne microbes

    by Kruttika S. Phadke, Deepak G. Madival, Janani Venkataraman, Debosmita Kundu, K. S. Ramanujan, Nisha Holla, Jaywant Arakeri, Gaurav Tomar, Santanu Datta, Arindam Ghatak

    Preventing nosocomial infection is a major unmet need of our times. Existing air decontamination technologies suffer from demerits such as toxicity of exposure, species specificity, noxious gas emission, environment-dependent performance and high power consumption. Here, we present a novel technology called “ZeBox” that transcends the conventional limitations and achieves high microbicidal efficiency. In ZeBox, a non-ionizing electric field extracts naturally charged microbes from flowing air and deposits them on engineered microbicidal surfaces. The surface’s three dimensional topography traps the microbes long enough for them to be inactivated. The electric field and chemical surfaces synergistically achieve rapid inactivation of a broad spectrum of microbes. ZeBox achieved near complete kill of airborne microbes in challenge tests (5–9 log reduction) and $$>90\%$$ > 90 % efficiency in a fully functional stem cell research facility in the presence of humans. Thus, ZeBox fulfills the dire need for a real-time, continuous, safe, trap-and-kill air decontamination technology.


  • Open Access

    Effectiveness of a novel non-intrusive continuous-use air decontamination technology to reduce microbial contamination in clinical settings: A multi-centric study

    by Savitha Nagaraj, Sindhulina Chandrasingh, Sanju Jose, Sofia B, Sriram Sampath, Bhuvana Krishna, Indira Menon, Debosmita Kundu, Sandeepan Parekh, Deepak Madival, et al.

    Background Despite rigorous disinfection, fumigation and air treatment, infectious microbial load has been found to circulate and survive for significant durations in health care settings. This raises significant concerns for hospital acquired infections. We have developed a novel, hybrid, trap- and-kill airborne-microbicidal technology called “ZeBox” which is efficient in clearing 99.999% of airborne microbial load under controlled lab conditions. In this study we evaluate the clinical performance of the ZeBox in reducing airborne and surface microbial load in two independent hospital settings. Methods The studies were conducted in single bed and multi bed ICU of two hospitals. Airborne and surface microbial loads were collected at pre-determined sampling sites pre- and post-deployment of the ZeBox enabled device. The Normality of data distribution was determined using the Shapiro-Wilk test. Statistical significance was determined using Students’ T test and Mann-Whitney’s U test. Pathogenic and opportunistic organisms were characterized using 16S rDNA sequencing. Furthermore, the antibiotic sensitivity of the isolated organisms was tested against current treatments of choice across major antibiotic classes. Results Post-deployment, we found statistically significant reductions in both airborne and surface microbial load within the operating range of the ZeBox enabled technology. Across the both hospital ICUs, there was 90% reduction of airborne microbial load on average, and 75% reduction of surface microbial load on average, providing a low bioburden zone of roughly 10-15 feet diameter around the unit. These reduced microbial levels were maintained during the entire duration of device operation over several weeks. Many of the clinical isolates recovered from one of the hospitals were drug resistant, which highlighted the potential ability of ZeBox to eliminate drug-resistant microbes and thereby reduce the frequency of hospital acquired infections. Conclusions ZeBox enabled technology can significantly reduce a broad spectrum of microbial burden in air and on surfaces in clinical settings. It can thereby serve an unmet need in reducing the incidence of hospital acquired infections.

  • Open Access

    ZeBox: A novel non-intrusive continuous-use technology to trap and kill airborne microbes

    by Kruttika S. Phadke, Deepak G. Madival, Janani Venkataraman, Debosmita Kundu, K. S. Ramanujan, Nisha Holla, Jaywant Arakeri, Gaurav Tomar, Santanu Datta, Arindam Ghatak

    Preventing nosocomial infection is a major unmet need of our times. Existing air decontamination technologies suffer from demerits such as toxicity of exposure, species specificity, noxious gas emission, environment-dependent performance and high power consumption. Here, we present a novel technology called “ZeBox” that transcends the conventional limitations and achieves high microbicidal efficiency. In ZeBox, a non-ionizing electric field extracts naturally charged microbes from flowing air and deposits them on engineered microbicidal surfaces. The surface’s three dimensional topography traps the microbes long enough for them to be inactivated. The electric field and chemical surfaces synergistically achieve rapid inactivation of a broad spectrum of microbes. ZeBox achieved near complete kill of airborne microbes in challenge tests (5-9 log reduction) and >90% efficiency in a fully functional stem cell research facility in the presence of humans. Thus, ZeBox fulfills the dire need for a real-time, continuous, safe, trap-and-kill air decontamination technology.


  • Open Access

    Trap and kill of environmental microbes: Validation of a novel decontamination technology in Hospital ICU setting

    by Sanju Jose, Kruttika S. Phadke, Janani Venkatraman, Bhuvana Krishna, Sriram Sampath, Santanu Datta, Savitha Nagaraj, Arindam Ghatak

    Nosocomial infections, also known as hospital-acquired infections (HAI), appear 48 hours or more after hospital admission and are independent of the original infirmity of the patient. To prevent or to reduce HAI, the central paradigm is to construct protective barriers between the large number of people who are sick and whose immune systems are compromised in the precincts of the hospital. Microbes that result in HAI do so by two routes of infection: touch and aerosol. We describe here ZeBox technology, a voltage induced synergistic killing of the microbe on designed surfaces, as a game-changer in this domain. Its kill rate is hitherto unmatched by any known chemical or non-chemical (viz; UV, ionisation) technology. In an enclosed test chamber, under challenge conditions, ZeBox technology can kill about a billion microbes in 10 minutes. When tested under clinical settings, the device could effectively reduce microbes, both from air and surfaces with more than 90% efficiency. The optimum requirement to reduce HAI would be to construct an online microbicidal device that operates in a continuous trap and kill mode in the background of people and patient movement, and decontaminates air and surfaces. We present unequivocal data to fortify our claims of online, continuous, safe, trap and kill mechanism of ZeBox technology.


  • Open Access

    Maximization of non-nitrogenous metabolite production in E. coli using population systems biology

    by Sreenath Rajagopal, Arindam Ghatak, Debdatto Mookherjee, Rothangmawi Victoria Hmar, Anirudh P. Shanbhag, Nainesh Katagihallimath, Janani Venkataraman, Ks Ramanujan, Santanu Datta

    The E. coli metabolome is an interconnected set of enzymes that has measurable kinetic parameters ascribed for the production of most of its metabolites. Flux Balance Analysis (FBA) or Ordinary Differential Equation (ODE) models are used to increase product yield using defined media. However, they either give a range (FBA) or exact amount (ODE) of metabolite yield which isn’t true as the transcriptome diversity of individual cells isn’t considered. We formulate the metabolic-behaviour of individual cells by using a POpulation SYstems-Biology ALgorithm (POSYBAL) which predicts multiple-gene knockouts for increasing industrially relevant metabolites. We validate this prediction for producing isobutanol (Heterogenous metabolite) and shikimate (Homogenous metabolite) where, the product-yield was increased by 40 times (~2000 ppm) and 42 times (~3000 ppm) respectively. Also, we introduce a nitrogen-swap in standard media to its low-nitrogen counterpart during post-growth phase to redistribute flux towards non-nitrogenous pathways for increasing overall product-yield. Further, our model shows growth-phase diversity in bacterial population even under normal glucose-uptake, portraying a real-world scenario of diverse and robust environment thus, making it evolutionarily favourable to threats such as anti-bacterial attack.

  • Open Access

    RAPD assisted selection of black gram (Vigna mungo L. Hepper) towards the development of multiple disease resistant germplasm

    by B. Vishalakshi, B. Umakanth, Anirudh P. Shanbhag, Arindam Ghatak, Nitish Sathyanarayanan, M. S. Madhav, G. Gopala Krishna, Hari Yadla

    Black gram (Vigna mungo L. Hepper), is an extensively studied food crop which is affected by many abiotic and biotic factors, especially diseases. The yield potential of Black gram is shallow due to lack of genetic variability and biotic stress susceptibility. Core biotic stress factors include mung bean yellow mosaic virus (MYMV), urdbean leaf crinkle virus (UCLV), wilt (Fusarium oxysporum) and powdery mildew (Erysiphe polygoni DC). Although many studies determine resistant varieties to a particular disease, however, it is often complimented by low yield and susceptibility to other diseases. Hence, this study focuses on investigating the genetic relationships among three varieties and nine accessions of black gram having disease resistance to previously described diseases and susceptibility using random amplified polymorphic deoxyribonucleic acid (RAPD) markers. A total of 33 RAPD primers were used for diversity analysis and yielded 206 fragments. Number of amplified fragments ranged from two (OPN-1) to 13 (OPF-1). The highest similarity coefficient was observed between IC-145202 and IC-164118 (0.921), while lowest similarity was between PU-31 and IC-145202 (0.572). The genetic diversity obtained in this study along with disease analysis suggests PU31as a useful variety for the development of markers linked to MYMV, UCLV, wilt and powdery mildew resistance by marker-assisted back cross breeding and facilitates the production of crosses with multiple disease resistance.


  • Open Access

    Delineating Substrate Diversity of Disparate Short-Chain Dehydrogenase Reductase from Debaryomyces hansenii

    by Arindam Ghatak, Nagakumar Bharatham, Anirudh P. Shanbhag, Santanu Datta, Janani Venkatraman

    Short-chain dehydrogenase reductases (SDRs) have been utilized for catalyzing the reduction of many aromatic/aliphatic prochiral ketones to their respective alcohols. However, there is a paucity of data that elucidates their innate biological role and diverse substrate space. In this study, we executed an in-depth biochemical characterization and substrate space mapping (with 278 prochiral ketones) of an unannotated SDR (DHK) from Debaryomyces hansenii and compared it with structurally and functionally characterized SDR Synechococcus elongatus. PCC 7942 FabG to delineate its industrial significance. It was observed that DHK was significantly more efficient than FabG, reducing a diverse set of ketones albeit at higher conversion rates. Comparison of the FabG structure with a homology model of DHK and a docking of substrate to both structures revealed the presence of additional flexible loops near the substrate binding site of DHK. The comparative elasticity of the cofactor and substrate binding site of FabG and DHK was experimentally substantiated using differential scanning fluorimetry. It is postulated that the loop flexibility may account for the superior catalytic efficiency of DHK although the positioning of the catalytic triad is conserved.